The Board of Directors of Bilcare Limited in their meeting held on Tuesday, 03 November 2026 have approved and taken on record Standalone and Consolidated Unaudited Financial Results of the Company for the period ended on 30 September 2026 and Limited Review Report issued by the Statutory Auditors of the Company and Change in Designation and Roles

B ilcare Bilcare Limited Tel +91 20 6600 7559 direct.bil@bilcare.com 301 Kamal Kunj www.bilcare-group.com R.u-earclv 8 Shivaji Housing Society Pune 411 016 India 03 November 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 526853 Sub: Outcome of Board Meeting held on 03 November 2026 Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI LODR Regulations, we hereby inform you that the Board of Directors, at its meeting held on 03 November 2026, has inter alia, approved the following matters: A. Unaudited Financial Results for the quarter and half year ended 30 September 2026 Pursuant to Regulation 33 of the SEBI LODR Regulations, we are enclosing herewith the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2026 along with the Statement of Assets and Liabilities (Standalone and Consolidated) as on 30 September 2026 and Cash Flow Statement (Standalone and Consolidated) for the said period, together with the Limited Review Report issued by the Statutory Auditors of the Company. The aforesaid financial results were recommended by the Audit Committee and were duly considered and approved by the Board of Directors of the Company at its meeting held on 03 November 2026. B. Change in Designation and Roles of Mr. Mohan Bhandari and Mr. Shreyans Bhandari: Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and as recommended by the Nomination and Remuneration Committee, we hereby inform you that the Board of Directors of the Company, at its meeting held on Tuesday, 03 November 2026, has appointed Mr. Mohan Bhandari as the Chairman of the Company with effect from 03 November 2026, in place of Mr. Shreyans Bhandari, Managing Director of the Company Accordingly, Mr. Shreyans Bhandari shall continue to be the Managing Director of the Company and Mr. Mohan Bhandari continues to hold the office of Director and Chief Executive Officer of the Company, with the additional responsibility of Chairmanship of the Company. The requisite details pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with the applicable SEBI circular are enclosed as Annexure A. The Board meeting commenced at 5.00 P.M. and concluded at 08:45 P.M. (IST). You are requested to take the same on record. Thanking you, Yours faithfully, For Bilcare Limited Mayur Dave Company Secretary & Compliance Officer Encl: as above Registered Office: 1028 Shiroli Rajgurunagar Pune 410 505 India Tel +91 2135 647501 CIN : L28939PN1987PLC043953 GST : 27AABCB2242F1Z6 B ilcare Bilcare Limited Tel +91 20 6600 7559 direct.bil@bilcare.com 301 Kamal Kunj www.bilcare-group.com R.u-earclv 8 Shivaji Housing Society Pune 411 016 India Annexure A Details under Regulation 30 of the SEBI Listing Regulations, read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Sr. Particulars Details 1. Name of Director / KMP Mr. Mohan Bhandari (DIN: 00052777) 2. Reason for change viz. Appointment as Chairman of the Company, in addition to his existing appointment, re-appointment, position as Director and CEO resignation, removal, death or otherwise 3. Date of appointment / re- Effective Date: 03 November 2026. appointment / cessation (as applicable) & term of appointment / re-appointment 4. Brief profile (in case of Mr. Mohan Bhandari is the Founder and Promoter of Bilcare Limited appointment) and the architect of Bilcare Research. A first-generation technocrat- entrepreneur with over 39 years of experience, he has guided the Company from its inception into an internationally recognized and respected enterprise, driven by the philosophy of “Transforming Innovations – Touching Lives.” Mr. Bhandari brings deep and diverse expertise across specialty materials, products, processes, services and technology, with a strong focus on translating scientific and technological capabilities into end-use applications for the pharmaceutical and healthcare sectors. His areas of expertise encompass materials science and specialty packaging engineering, anti-counterfeiting and brand- protection technologies, and global clinical supply-chain solutions. In recognition of his significant and sustained contribution to the pharmaceutical industry, he was conferred the Lifetime Achievement Award at the 59th Indian Pharmaceutical Conference in 2007. As Chairman, Mr. Mohan Bhandari will provide founder-led strategic direction, technical leadership and institutional continuity. His role will include strategic oversight of the Company’s robust and differentiated product portfolio, leveraging his extensive scientific and entrepreneurial experience, while continuing to nurture key global stakeholder relationships and support the Company’s long- term growth agenda. Mr. Mohan Bhandari will provide strategic leadership and Board-level guidance, leveraging his extensive industry experience and deep understanding of the Company. His continued involvement will strengthen Company’s material science-led growth strategy, particularly across high-growth segments of the pharmaceutical and healthcare industries strategic decision-making, execution of key initiatives, innovation and long-term growth. 5. Disclosure of relationships Mr. Mohan Bhandari is a Promoter of the Company and is related to between directors (in case of key board members as under: appointment of a Director) • Father of Mr. Shreyans Bhandari (Managing Director) • Father of Ms. Kavita Bhansali (Non-Executive Director) 6. Information required pursuant to Mr. Mohan Bhandari is not debarred from holding the office of BSE Circular ref no. Director by virtue of any SEBI order or any other such authority. LIST/COMP/14/2018-19 and NSE Circular ref no. NSE/CPL/2018/24 dated June 20, 2018 7. Shareholding in the Company 58,56,489 Equity Shares (24.87 %) Registered Office: 1028 Shiroli Rajgurunagar Pune 410 505 India Tel +91 2135 647501 CIN : L28939PN1987PLC043953 GST : 27AABCB2242F1Z6 Bilcare Limited Registered Office: 1028, Shiroli, Pune 410 505. Tel : +91 2135 647300 Fax: +912135 224068 Email : cs@bilcare.com Website: www.bilcare-group.com CIN : L28939PN1987PLC043953 A. Quarterly Integrated Filing (Financials) Unaudited Standalone Statement of Financial Results for the quarter and half year ended 30 September 2026 (Rs. in Crores) Quarter ended Half year ended Year ended Sr.No. Particulars 30 September 30June 30 September 30 September 30 September 31 March 2026 2026 2025 2026 2025 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1. Income Revenue from operations 1.93 1.94 1.85 3.87 3.92 6.85 Other Income 4.88 4.36 3.45 9.24 10.17 19.53 Total income 6.81 6.30 5.30 13.11 14.09 26.38 2. Expenses a. Cost of materials consumed 0.39 0.53 0.52 0.92 1.19 1.77 b. Changes in inventories of finished goods, work-in-progress and stock-in-trade C. Employee benefits expense 1.29 1.20 1.38 2.49 2.67 4.87 d. Finance costs 0.10 0.12 0.17 0.22 0.31 0.60 e. Depreciation and amortisation expense 0.60 0.60 0.72 1.20 1.40 2.72 f. Other expenses 1.12 1.20 1.31 2.32 2.83 12.70 Total expenses 3.50 3.65 4.10 7.15 8.40 22.66 3. Profit/ (Loss) before tax and exceptional items (1-2) 3.31 2.65 1.20 5.96 5.69 3.72 4. Exceptional items (0.90) (1.74) (2.64) (2.16) 5. Profit/ (Loss) before tax (3 + 4) 2.41 0.91 1.20 3.32 5.69 1.56 6. Tax expense 0.91 (0.13) 0.16 0.78 1.06 0.57 (i) Current tax (ii) Adjustment of tax relating to earlier years (iii) Deferred tax 0.91 (0.13) 0.16 0.78 1.06 0.57 7. Net Profit/ (Loss) for the period (5-6) 1.50 1.04 1.04 2.54 4.63 0.99 8. Other comprehensive income A (i) Items that will not be reclassified to profit or loss 0.03 (0.03) 0.37 (ii) Income tax relating to items that will not be reclassified to profit or loss (0.01) 0.01 (0.13) B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that wi [Showing first 8,000 characters — download PDF for full document]